Regeneron Maintains Its Momentum During Pandemic

The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.

Regeneron reported a solid first quarter • Source: Shutterstock

Regeneron Pharmaceuticals Inc. had strong revenue growth and made pipeline progress in the first quarter despite some headwinds caused by the COVID-19 pandemic. The big biotech reported Q1 revenue growth of 33% to $1.83bn on 5 May, even as its top-selling drug Eylea (aflibercept) faced some pressure late in the quarter from stay-at-home orders that resulted in some patients sitting out eye disease treatment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.